INTRODUCTION {#s1}
============

Cancers are serious problem around the world and complex, multistep, multifactorial, and highly fatal diseases. The environment and genetic inheritance have been known as risk factor in development of cancer \[[@R1]\]. Several recent studies focused on the genetic background and how the single nucleotide polymorphism (SNP) of specific genes, including DNA damage, can enhance cancer susceptibility \[[@R2]\].

DNA damage plays an important role in tumor development. Reactive oxygen species (ROS) increases damage to DNA and causes miscoding by DNA polymerase \[[@R3]\]. The level of ROS in tissue DNA reflects a balance between the rate of damage and repair. Abnormal balance results in DNA mutations that can activate oncogenes or inactivate tumor suppressor genes, which leads to cancer \[[@R4]\]. The base excision repair (BER) pathway is one of the DNA repair process. An important role of BER is to remove DNA damage caused by various carcinogens, such as ionizing radiation or reactive oxidative species \[[@R5]\]. BER has also evolved to cope with mutagenic and cytotoxic hydrolytic, oxidative, and alkylation damages. A relationship of BER to cancer progression has been drawn from the observation that mutations or altered expression in BER genes \[[@R6]\].

The hOGG1 is a DNA repair enzyme that excises 7,8-dihydro-8-oxoguanine (8oxoG) from DNA. The *hOGG1* is located on chromosome 3p26, a vital member of the BER pathway, and encodes 8-oxoguanine glycosylase that is a key enzyme in the repair of 8-oxoguanine \[[@R7]\]. ROS can lead to mutagenic base 8oxoG formation in DNA and carcinogenesis \[[@R8]\]. Since 8oxoG is a highly mispairing lesion, it was suggested that decreased hOGG1expression level could lead to a higher background mutation frequency and could possibly increase the cancer risk of an individual under oxidative stress \[[@R7]\].

Many previous studies showed the relationship between the Ser326Cys polymorphism of *hOGG1* gene and cancer susceptibility. Meta-analysis on the *hOGG1* polymorphism and the risk of bladder cancer shows no statistically significant association \[[@R9]\]. The meta-analysis on breast cancer suggested that the allele of *hOGG1* 326Cys plays a protective effect in European women but not in different menopausal status (premenopausal and postmenopausal) or the other ethnicities (Asians and Americans) \[[@R10]\]. The *hOGG1* polymorphism may be also contributed to the susceptibility of digestive cancers \[[@R11]\], colorectal cancer \[[@R12]\], esophageal squamous cell carcinoma \[[@R13]\] but shows a lack of association in gastric cancer \[[@R14]\]. In addition, the *hOGG1* polymorphism is associated with hepatocellular carcinoma \[[@R15]\], head and neck cancer \[[@R16]\], and prostate cancer \[[@R17]\], not with lung cancer \[[@R18]\].

Meta-analysis study in 2011 year reported that the evidence of the association between the *hOGG1* polymorphism and cancer risk \[[@R19]\]. Since 2011, many studies reported the relation between the *hOGG1* polymorphism and various cancer risks. However, the results have not been updated yet. Therefore, the purpose of this meta-analysis is to update previous meta-analysis with the aim of elucidating the association of the *hOGG1* polymorphism and risk of cancer.

RESULTS {#s2}
=======

In present study, we performed the meta-analysis to assess relationship between the *hOGG1* polymorphism and risk of cancer. We collected the genetic data from electronic databases. The search strategy used for this meta-analysis is shown in Figure [1](#F1){ref-type="fig"}. We examined the 577 articles and 442 articles were excluded as they were unrelated articles or duplicated studies. Among them, 19 studies were excluded because they were not consistent with Hardy-Weinberg equilibrium (HWE). After 116 articles were selected, 11 studies about the *hOGG1* polymorphism since 2012 were added. Finally, a total of 127 genetic studies about the *hOGG1* polymorphism and cancer were analyzed for meta-analysis ([Supplementary Table 1](#SD1){ref-type="supplementary-material"}) \[[@R5], [@R10]--[@R143]\]. [Supplementary Table 1](#SD1){ref-type="supplementary-material"} shows basic characteristics of the analyzed studies. The total 88,934 individuals comprised of 38,757 cancer patients and 50,177 control subjects. The types of cancers were including colorectal (18 articles), lung (28 articles), breast (16 articles), bladder (4 articles), gallbladder (2 articles), prostate (7 articles), gastric (13 articles), esophageal (10 articles), head and neck (8 articles), hepatocellular cancers (7 articles), and etc.

![Flow chart illustrating the search strategy used for this meta-analysis to identify studies that examined the association between *hOGG1* Ser326Cys polymorphism and risk of cancer](oncotarget-08-44761-g001){#F1}

Table [1](#T1){ref-type="table"} presents the results of meta-analysis of association between the *hOGG1* polymorphism and risk of cancer in allele (C *vs*. G), dominant (C/C genotype *vs*. C/G+G/G genotypes), and recessive (C/C+C/G genotypes *vs*. G/G genotype) models. The frequencies of major allele C/minor allele G in the total cancer and control were 63.33%/36.67%and 65.34%/34.66%. The minor G allele frequency in the total cancer was higher more than that of control (36.67% *vs*. 34.66%). The difference showed the significantly strong association with risk of cancer (OR=1.088, 95% CI=1.048-1.130, *p*\<0.001 in Table [1](#T1){ref-type="table"}). In the subgroup according to type cancer, as shown in Table [1](#T1){ref-type="table"}, colorectal cancer, lung cancer, prostate cancer and head and neck cancer presented the association with risk of cancer (colorectal cancer, OR=1.121, 95% CI=1.005-1.251, *p*=0.040; lung cancer, OR=1.094, 95% CI=1.020-1.172, *p*=0.012; prostate cancer OR=1.459, 95% CI=1.068-1.992, *p*=0.018; head and neck cancer, OR=1.335, 95% CI=1.079-1.651, *p*=0.008). The frequencies of CC genotype/CG+GG genotypes in the total cancer and control were 43.17%/56.83% and 45.02%/54.98%. The CG+GG genotypes frequency in the total cancer was higher more than that of control (56.83% *vs*. 54.98%). The difference showed the significant association with risk of cancer (OR=1.075, 95% CI=1.023-1.130, *p*=0.004 in Table [1](#T1){ref-type="table"}). In the subgroup according to type cancer, head and neck cancer only showed the association with risk of cancer (head and neck cancer, OR=1.424, 95% CI=1.099-1.845, *p*=0.007). The frequencies of CC+CG genotypes/GG genotype in the total cancer and control were 83.56%/16.44% and 85.69%/14.31%. The CG+GG genotypes frequency in the total cancer was higher more than that of control (16.44% *vs*. 14.31%). The difference showed the significant association with risk of cancer (OR=1.174, 95% CI=1.094-1.259, *p*\<0.001 in Table [1](#T1){ref-type="table"}). In the subgroup according to type cancer, lung cancer and head and neck cancer presented the association with risk of cancer (lung cancer, OR=1.188, 95% CI=1.055-1.337, *p*=0.004; head and neck cancer, OR=1.551, 95% CI=1.045-2.301, *p*=0.029).

###### Overall analysis between *hOGG1* Ser326Cys polymorphism and risk of cancer

  Cancers                        No. of studies   Heterogeneity   Model      OR (95% CI)   *p*                   
  ------------------------------ ---------------- --------------- ---------- ------------- --------------------- -------------
  *p*                            I-squared                                                                       
  C *vs*. G                                                                                                      
  All cancers                    125              \<0.001         61\. 138   Random        1.092 (1.051-1.134)   **\<0.001**
  Colorectal cancer              17               \<0.001         65.928     Random        1.121 (1.005-1.251)   **0.040**
  Lung cancer                    28               \<0.001         51.835     Random        1.094 (1.020-1.172)   **0.012**
  Breast cancer                  16               0.077           35.7       Fixed         1.031 (0.985-1.079)   0.185
  Bladder cancer                 4                0.004           77.187     Random        1.058 (0.812-1.379)   0.676
  Gallbladder cancer             2                0.015           83.061     Random        1.044 (0.877-1.242)   0.627
  Prostate cancer                6                \<0.001         79.676     Random        1.459 (1.068-1.992)   **0.018**
  Gastric cancer                 13               0.034           46.33      Random        1.011 (0.883-1.157)   0.874
  Esophageal cancer              10               0.112           37.044     Fixed         1.050 (0.957-1.152)   0.299
  Head and neck cancer           8                \<0.001         77.552     Random        1.335 (1.079-1.651)   **0.008**
  Hepatocellular cancer          7                \<0.001         74.985     Random        1.089 (0.883-1.344)   0.424
  Acute lymphoblastic leukemia   2                0.002           89.539     Random        1.579 (0.775-3.217)   0.208
  Pancreatic adenocarcinoma      2                0.467           \<0.001    Fixed         1.007 (0.885-1.146)   0.917
  C/C *vs*. C/G+G/G                                                                                              
  All cancers                    127              \<0.001         56.428     Random        1.079 (1.027-1.134)   **0.002**
  Colorectal cancer              18               \<0.001         60.869     Random        1.140 (0.993-1.308)   0.063
  Lung cancer                    28               0.004           47.036     Random        1.080 (0.984-1.187)   0.106
  Breast cancer                  16               0.202           22.109     Fixed         1.011 (0.948-1.078)   0.742
  Bladder cancer                 4                0.39            0.312      Fixed         1.000 (0.847-1.181)   0.996
  Gallbladder cancer             2                0.029           78.918     Random        1.080 (0.644-1.812)   0.771
  Prostate cancer                7                \<0.001         75.606     Random        1.401 (0.976-2.011)   0.067
  Gastric cancer                 13               0.346           9.913      Fixed         0.928 (0.821-1.048)   0.229
  Esophageal cancer              10               0.199           26.588     Fixed         0.971 (0.854-1.104)   0.652
  Head and neck cancer           8                \<0.001         74.243     Random        1.424 (1.099-1.845)   **0.007**
  Hepatocellular cancer          7                \<0.001         88.181     Random        1.113 (0.673-1.841)   0.677
  Acute lymphoblastic leukemia   2                0.006           86.606     Random        1.401 (0.583-3.364)   0.451
  Pancreatic adenocarcinoma      2                0.451           \<0.001    Fixed         1.051 (0.898-1.230)   0.539
  C/C+C/G *vs*. G/G                                                                                              
  All cancers                    125              \<0.001         54.586     Random        1.178 (1.098-1.263)   **\<0.001**
  Colorectal cancer              17               0.04            41.096     Random        1.154 (0.959-1.388)   0.129
  Lung cancer                    28               0.03            36.264     Random        1.188 (1.055-1.337)   **0.004**
  Breast cancer                  16               0.378           6.626      Fixed         1.092 (1.004-1.189)   0.041
  Bladder cancer                 4                \<0.001         86.372     Random        1.118 (0.557-2.246)   0.753
  Gallbladder cancer             2                0.074           68.567     Fixed         1.099 (0.761-1.585)   0.615
  Prostate cancer                6                0.003           72.07      Random        1.691 (0.965-2.965)   0.066
  Gastric cancer                 13               0.037           46.74      Random        1.088 (0.823-1.438)   0.553
  Esophageal cancer              10               0.02            54.195     Random        1.252 (0.929-1.686)   0.139
  Head and neck cancer           8                0.009           62.394     Random        1.551 (1.045-2.301)   **0.029**
  Hepatocellular cancer          7                \<0.001         85.472     Random        1.126 (0.723-1.754)   0.600
  Acute lymphoblastic leukemia   2                0.011           84.554     Random        2.435 (0.632-9.376)   0.196
  Pancreatic adenocarcinoma      2                0.809           \<0.001    Fixed         0.823 (0.578-1.172)   0.280

OR odds ratio, vs versus. Bold numbers indicate significant association with risk of cancer.

Table [2](#T2){ref-type="table"} and Table [3](#T3){ref-type="table"} present the results of meta-analysis of association between the *hOGG1* polymorphism and risk of cancer according to ethnic difference. In Asian population, analysis of allele, dominant, and recessive models showed the association with risk of cancer (C *vs*. G, OR=1.095, 95% CI=1.048-1.145, *p*\<0.001: CC *vs*. CG+GG, OR=1.096, 95% CI=1.015-1.183, p=0.019; CC+CG *vs*. GG, OR=1.171, 95% CI=1.070-1.282, *p*=0.001 in Table [2](#T2){ref-type="table"}). According to the type of cancer, risk of lung, breast, and head and neck cancers was associated with the *hOGG1* polymorphism (*p*\<0.05, Table [2](#T2){ref-type="table"}). In Caucasian population, analysis of allele and recessive models showed the association with risk of cancer (C *vs*. G, OR=1.097, 95% CI=1.021-1.179, *p*=0.012: CC+CG *vs*. GG, OR=1.158, 95% CI=1.005-1.334, *p*=0.043 in Table [3](#T3){ref-type="table"}). According to type of cancer, risk of colorectal, esophageal, and head and neck cancer was associated with the *hOGG1* polymorphism (*p*\<0.05, Table [3](#T3){ref-type="table"}). Begg\'s funnel plot and Egger\'s test were used to evaluate publication bias. The results of funnel plots and the Egger\'s test showed no publication bias in this meta-analysis except for allele model of all cancers (Figure [2](#F2){ref-type="fig"}). We found a weak publication bias in allele model of all cancers (*p* = 0.03425). In addition, 3 more subgroup analysis showed publication bias (recessive model of head and neck cancer and colorectal cancer in all population; recessive model of all cancer in Caucasian population, data not shown). In sensitivity analysis for our meta-analysis, some results were influenced by some studies. In all population analysis, allele model of lung, prostate, and head and neck cancer, dominant model of all cancers and head and neck cancer, and recessive model of all cancers, lung, and head and neck cancer were not influenced according to sensitivity analysis. In Asian population analysis, allele model of all cancers and lung cancer, dominant model of all cancers and head and neck cancer, and recessive model of all cancers, lung and breast cancer were not influenced. In Caucasian population analysis, allele model of all cancers and dominant model of esophageal cancer were not influenced by studies. These results indicate that individual with minor G allele of the *hOGG1* polymorphism may be increased risk of cancer.

###### Overall analysis between *hOGG1* Ser326Cys polymorphism and risk of cancer in Asian

  Cancers                 Comparison   Heterogeneity   Model     OR (95% CI)           *p*                   
  ----------------------- ------------ --------------- --------- --------------------- --------------------- -------------
  All cancers             C *vs*. G    \<0.001         44.278    Random                1.095 (1.048-1.145)   **\<0.001**
  CC *vs*. CG+GG          \<0.001      48.900          Random    1.096 (1.015-1.183)   **0.019**             
  CC+CG *vs*. GG          \<0.001      63.487          Random    1.171 (1.070-1.282)   **0.001**             
  Colorectal cancer       C *vs*. G    0.149           47.481    Fixed                 0.987 (0.879-1.108)   0.822
  CC *vs*. CG+GG          0.123        \<0.001         Fixed     1.068 (0.868-1.315)   0.532                 
  CC+CG *vs*. GG          0.451        \<0.001         Fixed     0.945 (0.795-1.122)   0.517                 
  Lung cancer             C *vs*. G    0.487           \<0.001   Fixed                 1.110 (1.048-1.176)   **\<0.001**
  CC *vs*. CG+GG          0.163        27.193          Fixed     1.116 (1.013-1.229)   **0.027**             
  CC+CG *vs*. GG          0.220        21.505          Fixed     1.176 (1.074-1.289)   **0.000**             
  Breast cancer           C *vs*. G    0.376           6.340     Fixed                 1.085 (1.013-1.162)   **0.019**
  CC *vs*. CG+GG          0.942        \<0.001         Fixed     1.098 (0.971-1.241)   0.135                 
  CC+CG *vs*. GG          0.108        44.685          Fixed     1.122 (1.014-1.242)   **0.026**             
  Bladder cancer          C *vs*. G    0.018           75.198    Random                1.135 (0.821-1.571)   0.444
  CC *vs*. CG+GG          0.848        \<0.001         Fixed     1.157 (0.910-1.472)   0.235                 
  CC+CG *vs*. GG          \<0.001      89.184          Random    1.264 (0.503-3.174)   0.619                 
  Gallbladder cancer      C *vs*. G    0.015           83.061    Random                1.108 (0.710-1.728)   0.652
  CC *vs*. CG+GG          0.029        78.918          Random    1.080 (0.644-1.812)   0.771                 
  CC+CG *vs*. GG          0.074        68.567          Fixed     1.099 (0.761-1.585)   0.615                 
  Gastric cancer          C *vs*. G    0.075           49.976    Fixed                 1.010 (0.904-1.129)   0.855
  CC *vs*. CG+GG          0.561        \<0.001         Fixed     0.977 (0.811-1.176)   0.802                 
  CC+CG *vs*. GG          0.012        65.907          Random    1.232 (0.823-1.843)   0.311                 
  Esophageal cancer       C *vs*. G    0.837           \<0.001   Fixed                 1.087 (0.980-1.205)   0.113
  CC *vs*. CG+GG          0.733        \<0.001         Fixed     1.017 (0.875-1.182)   0.821                 
  CC+CG *vs*. GG          0.031        56.757          Random    1.277 (0.939-1.735)   0.119                 
  Head and neck cancer    C *vs*. G    0.020           81.661    Random                1.499 (0.729-3.084)   0.271
  CC *vs*. CG+GG          0.274        16.259          Fixed     1.856 (1.262-2.731)   **0.002**             
  CC+CG *vs*. GG          0.124        57.636          Fixed     0.964 (0.696-1.335)   0.825                 
  Hepatocellular cancer   C *vs*. G    0.001           74.985    Random                1.089 (0.883-1.344)   0.424
  CC *vs*. CG+GG          \<0.001      89.658          Random    1.113 (0.673-1.841)   0.677                 
  CC+CG *vs*. GG          \<0.001      85.472          Random    1.126 (0.723-1.754)   0.600                 

OR odds ratio, vs versus. Bold numbers indicate significant association with risk of cancer.

###### Overall analysis between *hOGG1* Ser326Cys polymorphism and risk of cancer in Caucasian

  Cancers                     Comparison       Heterogeneity   Model     OR (95% CI)           *p*                   
  --------------------------- ---------------- --------------- --------- --------------------- --------------------- -----------
  All cancers                 C *vs*. G        \<0.001         68.987    Random                1.097 (1.033-1.166)   **0.002**
  CC *vs*. CG+GG              \<0.001          62.672          Random    1.078 (1.007-1.154    **0.031**             
  CC+CG *vs*. GG              \<0.001          45.629          Random    1.183 (1.053-1.331)   **0.004**             
  Colorectal cancer           C *vs*. G        \<0.001         74.844    Random                1.255 (1.053-1.497)   **0.011**
  CC *vs*. CG+GG              \<0.001          73.239          Random    1.234 (1.004-1.516)   **0.045**             
  CC+CG *vs*. GG              0.036            49.696          Random    1.509 (1.031-2.211)   **0.034**             
  Lung cancer                 C *vs*. G        \<0.001         74.319    Random                1.097 (0.920-1.309)   0.303
  CC *vs*. CG+GG              0.001            67.238          Random    1.081 (0.895-1.306)   0.420                 
  CC+CG *vs*. GG              0.034            50.306          Random    1.175 (0.814-1.696)   0.389                 
  Breast cancer               C *vs*. G        0.117           36.459    Fixed                 0.990 (0.932-1.053)   0.756
  CC *vs*. CG+GG              0.075            42.399          Fixed     0.980 (0.909-1.056)   0.596                 
  CC+CG *vs*. GG              0.728            \<0.001         Fixed     1.026 (0.880-1.197)   0.739                 
  Prostate cancer             C *vs*. G        \<0.001         90.407    Random                1.397 (0.702-2.780)   0.342
                              CC *vs*. CG+GG   0.001           85.774    Random                1.503 (0.734-3.078)   0.265
  CC+CG *vs*. GG              \<0.001          87.260          Random    1.604 (0.344-7.479)   0.548                 
  Gastric cancer              C *vs*. G        0.081           55.491    Fixed                 0.889 (0.752-1.050)   0.166
                              CC *vs*. CG+GG   0.131           56.157    Fixed                 0.880 (0.722-1.073)   0.207
  CC+CG *vs*. GG              0.467            \<0.001         Fixed     0.802 (0.498-1.292)   0.364                 
  Esophageal cancer           C *vs*. G        0.149           52.096    Fixed                 0.660 (0.482-0.904)   0.148
                              CC *vs*. CG+GG   0.102           51.614    Fixed                 0.627 (0.434-0.905)   **0.013**
  CC+CG *vs*. GG              0.943            \<0.001         Fixed     0.427 (0.144-1.263)   0.124                 
  Head and neck cancer        C *vs*. G        \<0.001         83.256    Random                1.396 (1.001-1.946)   **0.049**
                              CC *vs*. CG+GG   0.001           79.552    Random                1.406 (0.975-2.027)   0.068
  CC+CG *vs*. GG              0.014            67.859          Random    2.037 (1.047-3.960)   **0.036**             
  Pancreatic adenocarcinoma   C *vs*. G        0.562           \<0.001   Fixed                 1.007 (0.885-1.146)   0.917
                              CC *vs*. CG+GG   0.451           \<0.001   Fixed                 1.051 (0.898-1.230)   0.539
                              CC+CG *vs*. GG   0.809           \<0.001   Fixed                 0.823 (0.578-1.172)   0.280

OR odds ratio, vs versus. Bold numbers indicate significant association with risk of cancer.

![Begg\'s funnel plot for publication bias in selection of studies on the *hOGG1* Ser326Cys polymorphism (C *vs*. G, C/C *vs*. C/G+G/G, and C/C+C/G *vs*. G/G in all population)](oncotarget-08-44761-g002){#F2}

DISCUSSION {#s3}
==========

It was suggested that cancer susceptibility could result from the interaction of genetic background. Exposure and reductions in DNA repair capacity by common genetic variation affect cancer predisposition \[[@R6]\]. The hOGG1 is generally involved in DNA repair, and has been studied extensively on its relationship with various types of cancer. Low OGG activity in peripheral blood mononuclear cells increases risk of lung cancer \[[@R144]\]. Also, lower expression of hOGG1 mRNA and hOGG1 protein decreases mitochondrial DNA repair to oxidative damage in lung cancer cells \[[@R145]\]. Immunohistochemical expressions in diffuse-type adenocarcinoma of gastric cardia showed lower expression of OGG1, which related to higher T-stage, lymphatic invasion, and lymph node metastasis \[[@R146]\]. A previous study on lung cancer patients showed a close relationship between Ser326Cys polymorphism and OGG1 mRNA levels \[[@R57]\]. The Ser326Cys polymorphisms have been shown to be associated with delayed repair of oxidative DNA damage \[[@R147]\]. In a recent study, changes in the functional and structural characteristics of the hOGG1 protein by the Ser326Cys polymorphism using in silico computational biology tools have been reported. According to this study, *hOGG1* 326Cys variant is smaller and more hydrophobic than wild type, which can have deleterious effects on the function of the hOGG1 protein. And this variant has been found to be closely related to breast cancer \[[@R143]\]. Although the relationship between hOGG1 expression and cancer risk and the Ser326Cys *hOGG1* polymorphism and the expression of OGG1 has been reported, the results of previous genetic studies on the relationship between *hOGG1* polymorphism and various cancers risks were conflicting and contradictory. This meta-analysis was performed to provide a quantitative approach to for the different results.

Meta-analysis on the *hOGG1* polymorphism and the risk of bladder cancer, gastric cancer, and lung cancer shows no statistically significant association. But the other meta-analysis reported that the *hOGG1* polymorphism may contribute to the susceptibility of digestive cancers, breast cancer, colorectal cancer, esophageal squamous cell carcinoma, hepatocellular carcinoma, head and neck cancer, and prostate cancer. Among the previous meta-analysis studies, inappropriate data was included in the analysis. Therefore, there was error. For example, Zhu et al. 2012 investigated whether the *hOGG1* polymorphism was associated with prostate cancer using meta-analysis \[[@R17]\]. The meta-analysis included genotype data of rs3218997 SNP of *OGG1* that reported by Agalliu et al. 2010 \[[@R148]\]. Because rs3218997 SNP is different from Ser326Cys of *hOGG1*, the genetic data had to be excluded for the exact meta-analysis. In addition, some previous studies included articles which were not consistent with HWE. We evaluated HWE in all the articles, some articles were excluded. So, we performed this meta-analysis to combine and update from the different results.

In present study, total of 126 genetic studies about the *hOGG1* polymorphism and cancer were analyzed for meta-analysis. Significant relationship between the *hOGG1* polymorphism and overall cancer risk was found. In subgroup analyses by cancer types, the significant association between the *hOGG1* polymorphism and colorectal, lung, prostate, and head and neck cancer risk was detected. In addition, in subgroup analyses by ethnicities, we found that the *hOGG1* polymorphism was significantly associated with overall cancer risk in both Caucasian and Asian population. But there was a little different result between Asian and Caucasian population. In Asian population, lung, breast, and head and neck cancer showed a relation with the *hOGG1* polymorphism but in Caucasian population only head and neck cancer showed. On the other hands, an association with colorectal cancer and esophageal cancer was only shown in Caucasian population. Some our results were consistent with or contrary to previous meta-analysis. Overall cancer risk and the *hOGG1* polymorphism was significantly associated in our results (allele, *p*\<0.001; dominant, *p*=0.004; recessive, *p*\<0.001) and previous study showed similar result \[[@R19]\]. Results of previous meta-analysis on lung cancer were different from our present results \[[@R18]\]. Our results showed the statistically significance in lung cancer (allele and recessive model in overall analysis, allele, dominant, recessive model in Asian). It is seemed that it is because the previous study included some articles which were not in HWE in their meta-analysis. Meta-analysis on colorectal cancer was consistent with ours \[[@R12]\]. The *hOGG1* polymorphism had a connection with the colorectal cancer risk among the total population, and especially among Caucasians. One meta-analysis on breast cancer reported the association between the *hOGG1* polymorphism and breast cancer risk \[[@R10]\] but another study suggested a lack of association \[[@R149]\]. Our meta-analysis showed the different results. An association between the *hOGG1* polymorphism and breast cancer risk was found only in Asian population (allele, *p*=0.019; recessive model, *p*=0.026). Not only previous meta-analysis on bladder, gallbladder, and gastric cancer risk but also our present meta-analysis showed no statistically significance \[[@R9], [@R11], [@R14]\]. Zhang et al. reported the relation between the *hOGG1* polymorphism and esophageal cancer risk \[[@R13]\] but meta-analysis by Wang showed no association \[[@R11]\]. In our study, an association between the *hOGG1* polymorphism and esophageal cancer risk was found in dominant model in Caucasian population (*p*=0.013). Previous meta-analysis reported that the *hOGG1* polymorphism had a relation to hepatocellular cancer \[[@R15]\]. However, we could not find an association in any model. The results of previous meta-analysis on prostate cancer consisted with ours \[[@R17]\] but we could not find any association in Caucasian population and some studies influenced the results according to sensitivity analysis. Similar to previous study, our study showed the relation between the *hOGG1* polymorphism and head and neck cancer \[[@R16]\]. But recessive model in all population analysis showed publication bias and several results except for allele and dominant model in all population analysis and dominant model in Asian population analysis were influenced by some studies according to sensitivity analysis.

From dbSNP database, The C and G allele frequencies have been reported to be 0.776 and 0.224 in European, 0.500 and 0.500 in Chinese, 0.477 and 0.523 in Japanese, and 0.856 and 0.144 in Sub-Saharan African populations, respectively. And the CC, CG and GG genotype frequencies have been reported to be 0.621, 0.310, and 0.069 in European, 0.244, 0.511, and 0.244 in Chinese, 0.182, 0.591, and 0.227 in Japanese, and 0.746, 0.220, and 0.034 in Sub-Saharan African populations, respectively. In our results, the C and G allele frequencies have been reported to be 0.762 and 0.238 in Caucasian and 0.484 and 0.516 in Asian. And the CC, CG and GG genotype frequencies have been shown to be 0.584, 0.356, and 0.060 in Caucasian and 0.246, 0.477, 0.277 in Asian. We found that the genotype and allele frequencies in Caucasian and Asian showed significant difference, which might affect the roles of the *hOGG1* polymorphism on cancer risk in Asians and Caucasians.

This meta-analysis has several limitations. Our results showed the genetic difference and different cancer risks in ethnicity but included studies regarded only Caucasians and Asians, but not other races like African. Because of limited data, we simply divided the ethnicity into Asian and Caucasian. The genetic heterogeneity plays an important role in the carcinogenesis but it is an interaction between environment factors and genetic background. This analysis could not reflect environmental exposures. And there were considerable inadequate data in previous studies, especially in meta-analysis. We had examined the included articles as many as possible such as HWE or data in the article but there could be still omitted data. And several results showed significant associations but revealed publication bias.

CONCLUSIONS {#s4}
===========

In spite of some limitations, this meta-analysis could provide the evidence of the strong association between the *hOGG1* polymorphism and cancer risk. In summary, G allele of Ser326Cys polymorphism might play a role in the carcinogenesis and the genotype and allele frequencies difference makes the ethnicity difference in carcinogenesis. If further study with large sample size in diverse ethnic populations were performed, it would provide more precise understanding of the association between the *hOGG1* polymorphism and various cancer risks. This SNP could be a candidate of biomarker for cancer screening, diagnosis, and therapy in the future.

MATERIAL AND METHODS {#s5}
====================

Search strategy {#s5_1}
---------------

In order to select eligible studies about the *hOGG1* polymorphism and cancer, electronic database including Pubmed, Embase, google of scholar, and KISS were investigated up to April 2015. We searched meta-analysis study about the *hOGG1* polymorphism and also searched the association study between the *hOGG1* polymorphism and risk of cancer. The keywords to find these studies were following: "8-oxoguanine DNA glycosylase", "hOGG1", or "DNA repair gene", AND "polymorphism", "polymorphisms", or "variant" AND "Ser326Cys" AND "cancer or carcinoma", or "meta analysis". The previous meta-analysis studies about the *hOGG1* polymorphism and cancer were considered as reference.

Inclusion criteria and data extraction {#s5_2}
--------------------------------------

Selected studies were included in the meta-analysis if they met the following criteria: (1) Investigated the association study between the *hOGG1* polymorphism and cancer; (2) A comparison between cancer and control; (3) Included genotype and allele distributions of Ser326Cys polymorphism for genetic analysis. The data of first author\'s name, year of publication, country of origin, ethnicity of study population, sample size of cancer and control, and genotype frequencies of the *hOGG1* polymorphism in cancer and control were extracted from the final selected studies. The allele distributions were calculated from genotype distributions in the cancer group and the control group. The ethnicity was divided into Asian and Caucasian.

Statistical analysis {#s5_3}
--------------------

HWE in all include studies was tested by the Chi-square test. Meta-analysis was performed using the Comprehensive Meta-analysis software. The pooled p value, OR, and 95% CI were used to assess the strength of association between risk of cancer and the *hOGG1* polymorphism. All the results were re-analyzed to see the effect of each paper on the final results by sensitivity analysis. The meta-analysis was repeated while omitting each study one at a time to examine the influence of each study on the pooled OR. For the regression analysis in this meta-analysis, the random effects model or the fixed effects model was used. OR with the corresponding 95 % CI was calculated for the dominant model (C/C + C/G genotypes *vs*. G/G genotype) and recessive model (C/C *vs*. C/G + G/G genotypes), and allele (C *vs*. T), respectively \[[@R150],[@R151]\]. The *p*\<0.05 was regarded as statistically significant. A χ2-test-based Q statistic test was used to assess heterogeneity among studies. We also performed the effect of heterogeneity by *I*2 test. The random-effects Mantel--Haenszel method was adopted if the result of the Q test was p\<0.05 or *I*2 statistic was \>50 %, which indicated the statistically significant heterogeneity between the studies. Otherwise, the fixed-effects Mantel--Haenszel method was adopted. When more than 3 studies were included, Begg\'s funnel plot and Egger\'s test were performed to evaluated publication bias.
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